16. Measuring serum concentrations of Interleukin-15 in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis
Main Article Content
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse drug reactions, with immunological and genetic factors, including interleukin-15 (IL-15), implicated in their pathogenesis. In this cross-sectional descriptive study, serum IL-15 levels were measured by using the fluorescence covalent microbead immunosorbent assay (ProcartaPlex Immunoassay Panels kit, Thermo Fisher Scientific, USA) and its correlation with the disease severity was ana lyzed. The Mann-Whitney U test was used to compare mean and median values between groups, while the Spearman rank correlation test assessed correlations, with statistical significance considered at p-value < 0.05. A total of 61 patients (29 males and 32 females; 21 SJS patients and 40 TEN patients) with a median age of 51 years (interquartile range: 37 - 58) and 20 healthy controls were included in this study. The median lesional area was 45% of the body surface area (interquartile range: 8 - 70%). The median SCORTEN score was 2 (interquartile range: 1 - 2). The median serum concentration of IL-15 in SJS/TEN patients was 2.61 pg/ml (interquartile range: 1.49 - 4.04 pg/ml) and 2.61 pg/ml (interquartile range: 1.49 - 3.73 pg/ml) in TEN patients, not statistically higher than in the healthy control group. A correlation was observed between serum concentrations of IL-15 and the SCORTEN score in TEN patients.
Article Details
Keywords
Interleukin-15, SCORTEN, Steven-Johnson syndrome, toxic epidermal necrolysis
References
2. Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194-1227. doi:10.1111/bjd.14530
3. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343-1350. doi:10.1038/nm.1884
4. Nassif A, Bensussan A, Dorothée G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002;118(4):728-733. doi:10.1046/j.1523-1747.2002.01622.x
5. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol. 2004;114(5):1209-1215. doi:10.1016/j.jaci.2004.07.047
6. Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016;43(7):758-766. doi:10.1111/1346-8138.13 430
7. Su SC, Chung WH. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins. 2014;6(1):194-210. doi:10.3390/toxins6010194
8. Nguyen DV, Chu HC, Nguyen DV, et al. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015;5(2):68-77. doi:10.5415/apallergy.2015.5.2.68
9. Stern RS, Divito SJ. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done. J Invest Dermatol. 2017;137(5):1004-1008. doi:10.1016/j.jid.2017.01.003
10. Su SC, Mockenhaupt M, Wolkenstein P, et al. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol. 2017;137(5):1065-1073. doi:10.1016/j.jid.2016. 11.034
11. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-153. doi:10.1046/j.1523-1747. 2000.00061.x
12. Allard-Chamard H, Mishra HK, Nandi M, et al. Interleukin-15 in autoimmunity. Cytokine. 2020;136:155258. doi:10.1016/j.cyto. 2020.155258
13. Patidar M, Yadav N, Dalai SK. Interleukin 15: A key cytokine for immunotherapy. Cytokine Growth Factor Rev. 2016;31:49-59. doi:10.1016/j.cytogfr.2016.06.001
14. Sadek M, Iqbal O, Siddiqui F, et al. The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2021;27:1076029620950831. doi:10.1177/1076 029620950831